These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25888436)

  • 1. KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.
    Carter GC; Landsman-Blumberg PB; Johnson BH; Juneau P; Nicol SJ; Li L; Shankaran V
    J Exp Clin Cancer Res; 2015 Mar; 34(1):29. PubMed ID: 25888436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
    Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
    Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
    Han van Krieken J; Kafatos G; Bennett J; Mineur L; Tomášek J; Rouleau E; Fabian P; De Maglio G; García-Alfonso P; Aprile G; Parkar P; Downey G; Demonty G; Trojan J
    BMC Cancer; 2017 Nov; 17(1):798. PubMed ID: 29183279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka.
    Sirisena ND; Deen K; Mandawala DEN; Herath P; Dissanayake VHW
    BMC Res Notes; 2017 Aug; 10(1):392. PubMed ID: 28797274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations.
    Liang YH; Lin YL; Liau JY; Tsai JH; Liang JT; Lin BR; Hung JS; Tseng LH; Lin LI; Chang YL; Cheng AL; Yeh KH
    Anticancer Res; 2015 Jul; 35(7):4207-14. PubMed ID: 26124380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker Testing Disparities in Metastatic Colorectal Cancer.
    Sabbagh S; Herrán M; Hijazi A; Jabbal IS; Mohanna M; Dominguez B; Itani M; Sarna K; Liang H; Nahleh Z; Wexner SD; Nagarajan A
    JAMA Netw Open; 2024 Jul; 7(7):e2419142. PubMed ID: 38967928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA.
    Becker DJ; Lee KM; Lee SY; Lynch KE; Makarov DV; Sherman SE; Morrissey CD; Kelley MJ; Lynch JA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
    Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
    J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.
    Lièvre A; Artru P; Guiu M; Laurent-Puig P; Merlin JL; Sabourin JC; Viguier J; Bastie A; Seronde A; Ducreux M
    Eur J Cancer; 2013 Jun; 49(9):2126-33. PubMed ID: 23473612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.